Saffron is the dried stigma of Crocus sativus, long used as a spice and, more recently, as an extract standardised for its compounds crocin and safranal. Brands abroad ask for saffron because of a growing body of mood and sleep research, and because Japan has already accepted it into its function-claim system.
This guide is for brand owners planning a saffron product made in Japan. It covers what the meta-analyses show, Japan’s regulatory framing, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a saffron product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A meta-analysis of trials in people with poor sleep found saffron improved sleep quality and duration scores against placebo, and a separate meta-analysis found it reduced depression and anxiety inventory scores, though both bodies of evidence are rated low to moderate quality.
| Study | Design | Reported result |
|---|---|---|
| Systematic review and meta-analysis, International Journal of Environmental Research and Public Health 2022, 19(18):11658 (PMID 36141931) | 8 randomised trials, 431 participants with insomnia; saffron versus placebo | Improved sleep quality (6 studies, 308 participants, very low-quality evidence) and sleep duration (5 studies, 220 participants, moderate-quality evidence); effect on overall insomnia severity did not reach significance |
| Meta-analysis, Complementary Therapies in Medicine 2020;48:102250 (PMID 31987241) | 21 randomised trials of saffron supplementation and depression, anxiety or C-reactive protein | Significant reduction in Beck Depression Inventory and Beck Anxiety Inventory scores, and in Pittsburgh Sleep Quality Index scores; no significant effect on C-reactive protein |
Two caveats to keep in view:
- Trial quality and heterogeneity. The insomnia meta-analysis graded its sleep-quality finding as very low-quality evidence, and both reviews reported meaningful heterogeneity between the pooled trials.
- Population. Much of the pooled evidence comes from adults with diagnosed insomnia or depression, not healthy people managing everyday stress. That is a fact about the research population, not a basis for a disease claim on a food product.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Saffron-derived crocin and safranal are notified functional ingredients under Japan’s Foods with Function Claims system, for functions including easing daytime sleepiness, supporting motivation, and sleep quality measures such as depth of sleep and how refreshed a person feels on waking.
As with other notified ingredients, the business that notifies the product is responsible for the scientific evidence behind the stated function, submitted to the Consumer Affairs Agency before sale. The accepted wording describes everyday states — daytime sleepiness, motivation, sleep depth and morning freshness — not a mood or sleep disorder.
Two lessons for a brand abroad:
- The notified wording is deliberately modest, describing everyday states rather than a clinical outcome. Copying it into stronger language elsewhere goes beyond what either the notification or the meta-analyses support.
- A Japanese notification is a Japanese mechanism for products sold in Japan, not a global endorsement. Your label abroad follows your own market’s rules.
💬 Need an evidence summary for your regulatory adviser that separates the Japanese notification from the independent meta-analyses? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe saffron by the everyday states it has been studied for, not by a mood or sleep disorder it would treat.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for sleep quality and daytime alertness” | Names of sleep or mood disorders, or “treats” anything |
| ”Contains saffron extract standardised for crocin and safranal”, with the amount per serving | ”Clinically proven” without naming the study and its limits |
| Citing the specific meta-analysis and noting the evidence grade | Presenting pooled results from patients with a diagnosed condition as evidence for a healthy-population product |
How saffron is formulated
Saffron extract is dosed in tens of milligrams a day and is typically standardised for its crocin and safranal content, so it fits small tablets and capsules easily.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Tablet | Small daily serving, low cost per day | Standard format for a sleep or mood-support supplement |
| Hard capsule | Simple, flavourless | Suits combined relaxation formulas |
Decisions that shape the specification:
- Standardisation. Ask the supplier for the crocin and safranal content the extract is standardised to, and confirm it is derived from the stigma rather than other parts of the plant.
- Amount per serving. Saffron trials commonly use doses in the range of around 30 mg a day of extract; match the amount to a study you intend to cite.
- Companion ingredients. Saffron is often combined with other relaxation ingredients. Every herbal companion needs its own check against Japanese food law — some botanicals sold freely elsewhere are treated as medicines in Japan.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Saffron stigma extract itself is used in Japanese foods and is a notified Foods with Function Claims ingredient. Companion botanicals in a “relax” or “sleep” formula are where a problem is more likely to appear. See the Japan-made supplement OEM page, and our GABA and theanine guides for other sleep-themed ingredients Japan can manufacture as foods.
Before you ask for a quotation
A factory can quote accurately once the standardisation, the amount, the form and the companions are fixed.
- Saffron extract standardisation (crocin/safranal content) and plant part
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Countries you will sell in, and saffron’s status there
- First order and annual volume
💬 Ready to design a Japan-made saffron product? Send us the concept — amount, form, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does saffron help with sleep?
A 2022 meta-analysis of 8 trials in 431 people with insomnia found improved sleep quality and duration scores against placebo, though the sleep-quality finding was graded very low-quality evidence. Describe saffron as studied for sleep quality, not as a proven insomnia remedy.
2. Does saffron help with mood?
A 2020 meta-analysis of 21 trials found reduced depression and anxiety inventory scores with saffron supplementation. Much of this evidence comes from people with diagnosed depression, so a food product should describe everyday mood balance rather than any diagnosis.
3. Is saffron permitted as a food ingredient in Japan?
Yes. Saffron-derived crocin and safranal are notified functional ingredients under Japan’s Foods with Function Claims system, accepted for functions such as daytime alertness and sleep quality.
4. What dose of saffron do studies use?
Trials in the meta-analyses reviewed for this guide commonly used saffron extract in the tens-of-milligrams range per day. Match your formula’s amount to the specific study you plan to cite.
5. Can saffron be combined with other relaxation ingredients?
Yes, but each companion ingredient needs its own check against Japanese food law. Some botanicals sold freely elsewhere are classified as medicines in Japan and would stop the whole product being made as a food there.
Sources: “Crocus Sativus for Insomnia: A Systematic Review and Meta-Analysis”, International Journal of Environmental Research and Public Health 2022, 19(18):11658 (PMID 36141931); “The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials”, Complementary Therapies in Medicine 2020;48:102250 (PMID 31987241); Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 25 September 2026.